Immunovant CFO sells shares for RSU tax cover

Immunovant, Inc. Chief Financial Officer Tiago Girao reported an open-market sale of 25,760 shares of common stock at a weighted average price of $29.62 per share.

Rhea-AI Filing Summary

Immunovant, Inc. Chief Financial Officer Tiago Girao reported an open-market sale of 25,760 shares of common stock at a weighted average price of $29.62 per share. After this transaction, he directly holds 247,596 shares.

According to the footnotes, this sale was executed solely to cover tax withholding obligations tied to the vesting and settlement of 52,097 restricted stock units from a prior grant of 208,388 RSUs. The company required a “sell to cover” transaction, so the sale is described as non-discretionary for the executive.

Insider Trade Summary

Net Seller: 25,760 shares

Net Sell 1 txn

Insider Girao Tiago

Role Chief Financial Officer

Sold 25,760 shs ($763K)

Type	Security	Shares	Price	Value
Sale	Common Stock	25,760	$29.62	$763K

Holdings After Transaction: Common Stock — 247,596 shares (Direct)

Footnotes (2)

1. F1. On May 1, 2025, the holder was granted 208,388 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on May 5, 2025, of which 52,097 of these RSUs vested on April 21, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.23 - $30.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Key Figures

Shares sold: 25,760 shares Weighted average sale price: $29.62 per share Shares held after transaction: 247,596 shares +3 more

6 metrics

Shares sold 25,760 shares Open-market sale to cover RSU tax withholding

Weighted average sale price $29.62 per share Common stock sale

Shares held after transaction 247,596 shares Direct holdings post-sale

RSU grant size 208,388 RSUs Grant on May 1, 2025

RSUs vested 52,097 RSUs Vested on April 21, 2026

Sale price range $29.23–$30.00 per share Range for multiple transactions

Key Terms

restricted stock units, sell to cover, weighted average price, open-market sale

4 terms

restricted stock units financial

"the holder was granted 208,388 restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"tax withholding obligations to be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immunovant (IMVT) CFO Tiago Girao report in this Form 4?

Immunovant CFO Tiago Girao reported selling 25,760 shares of common stock at a weighted average price of $29.62. The footnotes explain the sale was to cover tax withholding on vested RSUs, not a discretionary trade.

Why did Immunovant (IMVT) CFO sell 25,760 shares of stock?

The 25,760 shares were sold to cover tax withholding obligations on vested restricted stock units. Immunovant elected to satisfy these taxes through a mandatory “sell to cover” transaction, so the sale was not a voluntary portfolio decision by the CFO.

How many Immunovant (IMVT) shares does the CFO hold after the sale?

After the transaction, CFO Tiago Girao directly holds 247,596 shares of Immunovant common stock. This figure reflects his position following the 25,760-share sale executed to fund tax withholding on recently vested restricted stock units.

What RSU grant is referenced in Immunovant (IMVT) CFO’s Form 4?

The filing notes a grant of 208,388 restricted stock units awarded on May 1, 2025. Of this grant, 52,097 RSUs vested on April 21, 2026, and the tax obligations from that vesting triggered the mandatory sell-to-cover stock sale.

At what prices were Immunovant (IMVT) shares sold in this Form 4?

The reported weighted average sale price was $29.62 per share. Footnotes clarify that multiple trades occurred within a range from $29.23 to $30.00 per share, and detailed breakdowns are available from the company or the reporting person upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Girao Tiago

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/23/2026		S		25,760(1)	D	$29.62(2)	247,596	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On May 1, 2025, the holder was granted 208,388 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on May 5, 2025, of which 52,097 of these RSUs vested on April 21, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.23 - $30.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

	/s/ Tiago Girao	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)